Biomarkers of Cognitive Impairment in Blood Cells

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-01

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to identify transcriptomic biomarkers in blood cells to diagnose early cognitive impairment. This would allow preventing the development of severe pathologies, such as Alzheimer Disease. In addition, this project will analyse the influence of adiposity, obesity, nutritional habits and physical activity on cognition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitorign of Patients With a Neurodegenerative Disease or Mental Disorder

NCT07314190

Alzheimer Disease Dementia With Lewy Bodies (DLB) Frontotemporal Dementia (FTD) +4 more

ENROLLING_BY_INVITATION

Biomarker Study to Diagnose Alzheimer's Disease

NCT01874418

Alzheimer Disease Mild Cognitive Impairment

UNKNOWN NA

β-AARC: Cohort Study for the Identification of Blood-based Biomarkers in a Population With Subjective Cognitive Decline

NCT04935372

Alzheimer Disease Preclinical Alzheimer Mild Cognitive Impairment

ACTIVE_NOT_RECRUITING

Biomarker Study for Alzheimer's Disease

NCT02472899

Alzheimer's Disease

COMPLETED

Study to Understand Novel Biomarkers in Researching Dementia

NCT06547099

Alzheimer Disease Mild Cognitive Impairment Dementia

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Blood cells constitute a minimally invasive material, which is presented as potentially suitable for addressing the identification of clinical diagnostic biomarkers. This study will compare gene expression in blood cells of patients with various degrees of cognitive alteration (mild cognitive impairment due to Alzheimer's disease and dementia due to Alzheimer's Disease) compared to control individuals, to identify early biomarkers of impaired cognition. The availability of non-invasive early biomarkers of cognitive dysfunction is highly relevant in the field of public health, from the point of view of being able to prevent or delay the onset and/or progression of dementia and other cognitive disorders. In addition, it is intended to establish the association between the biomarkers identified with nutritional imbalances and increased adiposity/obesity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment Due to Alzheimer's Disease Dementia Due to Alzheimer's Disease (Disorder)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

20 individuals with no cognitive alterations or any other pathology which could alter cognitive performance or blood cells

No intervention will be performed.

Intervention Type OTHER

No intervention will be performed.

Mild Cognitive Impairment Due to Alzheimer's Disease: MCI group

20 individuals diagnosed with Mild Cognitive Impairment Due to Alzheimer's Disease with positive AD markers in cerebrospinal fluid

No intervention will be performed.

Intervention Type OTHER

No intervention will be performed.

Dementia due to Alzheimer Disease: AD group

20 individuals diagnosed with Dementia Due to Alzheimer Disease with positive AD markers in cerebrospinal fluid

No intervention will be performed.

Intervention Type OTHER

No intervention will be performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention will be performed.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 55-80 years
* Absence of cognitive symptoms
* Normal neuropsychological examination, (Clinical Dementia Rating, CDR = 0)

* Age between 55-80 years
* Established diagnosis of MCI
* Cognitive deficit of 1.5 standard deviation in at least one of the neuropsychological tests performed, with no relevant functional repercussion (Functional Activities Questionnaire, FAQ\<7 and CDR≤0.5)
3. Group with Dementia Due to Alzheimer Disease (AD)

* Age between 55-80 years
* Established diagnosis of Alzheimer's disease
* CDR ≥ 0.5 and positive AD markers in cerebrospinal fluid

Exclusion Criteria

* Any disease that could influence their cognitive performance or blood cell parameters.
2. Group with Mild Cognitive Impairment Due to Alzheimer's Disease (MCI group)

Minimum Eligible Age

55 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes